In This Article:
What Happened?
Shares of animal health company Zoetis (NYSE:ZTS) fell 10.6% in the morning session after the company reported disappointing fourth-quarter results: its full-year EPS and revenue guidance fell short of Wall Street's estimates. Revenue grew 5% year over year, as weakness in livestock sales, which declined due to the divestiture of certain products, was partly offset by strength in the companion animal segment. Looking ahead, Zoetis expects 6% to 8% organic operational revenue growth, but foreign exchange pressures and ongoing challenges could create headwinds. Overall, this quarter could have been better.
The shares closed the day at $164.93, down 5.1% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Zoetis? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Zoetis’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Zoetis and indicate this news significantly impacted the market’s perception of the business.
Zoetis is up 1.3% since the beginning of the year, but at $164.77 per share, it is still trading 17.6% below its 52-week high of $199.94 from February 2024. Investors who bought $1,000 worth of Zoetis’s shares 5 years ago would now be looking at an investment worth $1,137.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.